End-stage renal disease after treatment with 90 Y-DOTATOC

Markus Cybulla(University Medical Center Freiburg), Stefan M. Weiner(University Medical Center Freiburg), Andreas Otte

European Journal of Nuclear Medicine and Molecular Imaging

October 1, 2001

10.1007/s002590100599

Cited by 152

Abstract

Related Papers

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

Andreas Otte, R Herrmann, A Heppeler et al.|PubMed|1999|370

Yttrium-90-labelled somatostatin-analogue for cancer treatment

Andreas Otte, Jan Mueller‐Brand, Sophie Dellas et al.|The Lancet|1998|334

DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy

Andreas Otte, E. Jermann, Martin Béhé et al.|European Journal of Nuclear Medicine and Molecular Imaging|1997|214

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

Giovanni Paganelli, Stefania Zoboli, Marta Cremonesi et al.|European Journal of Nuclear Medicine and Molecular Imaging|2001|205

RADIATION NEPHRITIS

R.W. Luxton|The Lancet|1961|113